Quantedge Capital Pte Ltd Makes New Investment in Omnicell, Inc. (NASDAQ:OMCL)

Quantedge Capital Pte Ltd purchased a new position in Omnicell, Inc. (NASDAQ:OMCL - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 75,600 shares of the company's stock, valued at approximately $3,366,000. Omnicell comprises 1.2% of Quantedge Capital Pte Ltd's portfolio, making the stock its 23rd biggest holding. Quantedge Capital Pte Ltd owned approximately 0.16% of Omnicell as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also made changes to their positions in the company. Smartleaf Asset Management LLC raised its holdings in Omnicell by 51.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock worth $35,000 after acquiring an additional 273 shares during the period. Johnson Financial Group Inc. acquired a new position in Omnicell during the fourth quarter worth $37,000. Van ECK Associates Corp increased its holdings in shares of Omnicell by 47.0% during the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company's stock worth $44,000 after buying an additional 315 shares in the last quarter. Headlands Technologies LLC bought a new position in shares of Omnicell in the fourth quarter valued at about $53,000. Finally, First Horizon Advisors Inc. raised its stake in shares of Omnicell by 36.3% in the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock worth $59,000 after acquiring an additional 355 shares during the last quarter. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Omnicell Stock Down 0.8%

OMCL stock traded down $0.22 during mid-day trading on Monday, hitting $27.74. 145,934 shares of the company were exchanged, compared to its average volume of 557,766. The firm has a market cap of $1.30 billion, a P/E ratio of 102.87, a P/E/G ratio of 7.53 and a beta of 0.78. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. Omnicell, Inc. has a 1-year low of $22.66 and a 1-year high of $55.75. The firm's 50 day simple moving average is $31.41 and its 200 day simple moving average is $39.40.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $0.26 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.16 by $0.10. The company had revenue of $269.67 million for the quarter, compared to analysts' expectations of $260.18 million. Omnicell had a return on equity of 3.82% and a net margin of 1.13%. The business's revenue was up 9.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.03 EPS. On average, sell-side analysts predict that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently commented on OMCL. Wells Fargo & Company upgraded Omnicell from an "equal weight" rating to an "overweight" rating and lifted their price objective for the stock from $31.00 to $35.00 in a research report on Wednesday, May 14th. JPMorgan Chase & Co. cut their target price on Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a research note on Thursday, March 20th. Benchmark decreased their target price on Omnicell from $62.00 to $40.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Finally, StockNews.com downgraded shares of Omnicell from a "buy" rating to a "hold" rating in a research report on Saturday, May 3rd. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $46.50.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.